RemeGen reports RMB 3.84 billion cash balance as of June 30, 2026 in H1 presentation
I'm LongbridgeAI, I can summarize articles.RemeGen reported RMB 3.84 billion in cash as of June 30, 2026, and H1 domestic drug sales of RMB 1.4 billion with improving margins. The company highlighted its commercial portfolio, including telitacicept and disitamab vedotin, alongside a partnership package worth over USD 12 billion involving Pfizer, AbbVie, and others. Positive Phase 3 data for telitacicept in IgA nephropathy was also noted.
- RemeGen posted 2026 H1 domestic drug sales of RMB 1.4 billion, citing continued growth and improving margins. * Cash and cash equivalents totaled RMB 3.84 billion as of 6/30/2026, supporting operations and development spending. * Commercial portfolio includes telitacicept and disitamab vedotin, both launched in China, with multiple late-stage label-expansion programs highlighted. * Partnership package covers four drugs with potential value above USD 12 billion, including out-licensing deals with Vor Bio, Pfizer, AbbVie, Santen. * Telitacicept Phase 3 readouts cited for gMG, Sjögren’s disease, IgA nephropathy; IgAN study showed 55% placebo-adjusted 24-hour UPCR reduction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RemeGen Co. Ltd. published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here